BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 38665016)

  • 1. Epithelial-Mesenchymal Transformation Promotes the Progression of Hepatocellular Carcinoma through NF-κB/MMP9 Axis.
    Li J; Cai Q; Wang Z; Wang L; Yang G; Zhang Z; Ge N; Hu S; Bai T
    Discov Med; 2024 Apr; 36(183):666-677. PubMed ID: 38665016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RANKL promotes migration and invasion of hepatocellular carcinoma cells via NF-κB-mediated epithelial-mesenchymal transition.
    Song FN; Duan M; Liu LZ; Wang ZC; Shi JY; Yang LX; Zhou J; Fan J; Gao Q; Wang XY
    PLoS One; 2014; 9(9):e108507. PubMed ID: 25268581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppressive effects of microRNA-16 on the proliferation, invasion and metastasis of hepatocellular carcinoma cells.
    Wu WL; Wang WY; Yao WQ; Li GD
    Int J Mol Med; 2015 Dec; 36(6):1713-9. PubMed ID: 26499886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-5692a promotes the invasion and metastasis of hepatocellular carcinoma via MMP9.
    Sun SJ; Wang N; Sun ZW; Chen J; Cui HW
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4869-4878. PubMed ID: 30070322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
    Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
    EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TRIM66 promotes malignant progression of hepatocellular carcinoma by inhibiting E-cadherin expression through the EMT pathway.
    Zhang HG; Pan YW; Feng J; Zeng CT; Zhao XQ; Liang B; Zhang WW
    Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2003-2012. PubMed ID: 30915743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FoxM1 overexpression promotes epithelial-mesenchymal transition and metastasis of hepatocellular carcinoma.
    Meng FD; Wei JC; Qu K; Wang ZX; Wu QF; Tai MH; Liu HC; Zhang RY; Liu C
    World J Gastroenterol; 2015 Jan; 21(1):196-213. PubMed ID: 25574092
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MiR-16 inhibits hepatocellular carcinoma progression by targeting FEAT through NF-κB signaling pathway.
    Su XF; Li N; Meng FL; Chu YL; Li T; Gao XZ
    Eur Rev Med Pharmacol Sci; 2019 Dec; 23(23):10274-10282. PubMed ID: 31841182
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAX-1 promotes the migration and invasion of hepatocellular carcinoma cells through the induction of epithelial-mesenchymal transition via the NF-κB pathway.
    Hu YL; Feng Y; Ma P; Wang F; Huang H; Guo YB; Li P; Mao QS; Xue WJ
    Exp Cell Res; 2019 Aug; 381(1):66-76. PubMed ID: 31047882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AQP5 promotes hepatocellular carcinoma metastasis via NF-κB-regulated epithelial-mesenchymal transition.
    He Z; Dong W; Hu J; Ren X
    Biochem Biophys Res Commun; 2017 Aug; 490(2):343-348. PubMed ID: 28619511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RUFY3 promotes the progression of hepatocellular carcinoma through activating NF-κB-mediated epithelial-mesenchymal transition.
    Zhang Y; Ni W; Qin L
    Aging (Albany NY); 2021 Sep; 13(17):21283-21293. PubMed ID: 34510031
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of the long non-coding RNA SPRY4-IT1 promotes tumor cell proliferation and invasion by activating EZH2 in hepatocellular carcinoma.
    Zhou M; Zhang XY; Yu X
    Biomed Pharmacother; 2017 Jan; 85():348-354. PubMed ID: 27899259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MAP4K4 promotes epithelial-mesenchymal transition and metastasis in hepatocellular carcinoma.
    Feng XJ; Pan Q; Wang SM; Pan YC; Wang Q; Zhang HH; Zhu MH; Zhang SH
    Tumour Biol; 2016 Aug; 37(8):11457-67. PubMed ID: 27010469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IGFBP2 upregulates ZEB1 expression and promotes hepatocellular carcinoma progression through NF-κB signaling pathway.
    Guo Q; Yu DY; Yang ZF; Liu DY; Cao HQ; Liao XW
    Dig Liver Dis; 2020 May; 52(5):573-581. PubMed ID: 31818638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 14-3-3β Promotes Migration and Invasion of Human Hepatocellular Carcinoma Cells by Modulating Expression of MMP2 and MMP9 through PI3K/Akt/NF-κB Pathway.
    Tang Y; Lv P; Sun Z; Han L; Zhou W
    PLoS One; 2016; 11(1):e0146070. PubMed ID: 26730736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plumbagin promotes human hepatoma SMMC-7721 cell apoptosis via caspase-3/vimentin signal-mediated EMT.
    Wei Y; Lv B; Xie J; Zhang Y; Lin Y; Wang S; Zhong J; Chen Y; Peng Y; Ma J
    Drug Des Devel Ther; 2019; 13():2343-2355. PubMed ID: 31409969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator Twist1.
    Zhao XL; Sun T; Che N; Sun D; Zhao N; Dong XY; Gu Q; Yao Z; Sun BC
    J Cell Mol Med; 2011 Mar; 15(3):691-700. PubMed ID: 20219012
    [TBL] [Abstract][Full Text] [Related]  

  • 18. β-Patchoulene represses hypoxia-induced proliferation and epithelial-mesenchymal transition of liver cancer cells.
    Tu H; Wang W; Feng Y; Zhang L; Zhou H; Cheng C; Ji L; Cai Q; Feng Y
    Bioengineered; 2022 May; 13(5):11907-11922. PubMed ID: 35546067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of COX-2 expression and epithelial-to-mesenchymal transition by hypoxia-inducible factor-1α is associated with poor prognosis in hepatocellular carcinoma patients post TACE surgery.
    Huang M; Wang L; Chen J; Bai M; Zhou C; Liu S; Lin Q
    Int J Oncol; 2016 May; 48(5):2144-54. PubMed ID: 26984380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
    Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.